Clinical Updates

Mild respiratory COVID can cause multi-lineage neural cell and myelin dysregulation | Health Impairments in Children and Adolescents After Hospitalization for Acute COVID-19 or MIS-C | Duration of Shedding of Culturable Virus in SARS-CoV-2 Omicron (BA.1) Infection | Children and COVID-19: State level Data Report | COVID-19 rebound after Paxlovid and Molnupiravir during January-June 2022 | Comparative Effectiveness of the SARS-CoV-2 Vaccines During Delta | In adults hospitalized with COVID-19, high- vs low-dose venous thromboprophylaxis reduces venous thromboembolism but increases major bleeding

Children and COVID-19: State level Data Report | Effect of a 2-week interruption in methotrexate treatment versus continued treatment on COVID-19 booster vaccine immunity in adults with inflammatory conditions (VROOM study): a randomized, open label, superiority trial | Pediatric SARS-CoV-2 Seroprevalence in Arkansas Over the First Year of the COVID-19 Pandemic and Antibody Responses to SARS-CoV-2 in Children With COVID-19 | All-Cause Maternal Mortality in the US Before vs During the COVID-19 Pandemic

Outcomes of SARS-CoV-2 Reinfection | Children and COVID-19: State level Data Report | CDC Recommends COVID-19 Vaccines for Young Children | Evaluating clinical effectiveness of SARS-CoV-2 vaccine in solid organ transplant recipients: A propensity score matched analysis | Therapeutic efficacy of monoclonal antibodies and antivirals against SARS-CoV-2 Omicron BA.1 in Syrian hamsters | Rebound Phenomenon after Nirmatrelvir/Ritonavir Treatment of Coronavirus Disease-2019 in High-Risk Persons | Hospitalization and Emergency Department Encounters for COVID-19 After Paxlovid Treatment — California, December 2021–May 2022

Ivermectin for Treatment of Mild-to-Moderate COVID-19 in the Outpatient Setting: A Decentralized, Placebo-controlled, Randomized, Platform Clinical Trial | Persistence of residual SARS-CoV-2 viral antigen and RNA in tissues of patients with long COVID-19 | Intramuscular AZD7442 (Tixagevimab–Cilgavimab) for Prevention of Covid-19 | Rebound Phenomenon after Nirmatrelvir/Ritonavir Treatment of Coronavirus Disease-2019 in High-Risk Persons | The anti-SARS-CoV-2 monoclonal antibody, bamlanivimab, minimally impacts the endogenous immune response to COVID-19 vaccination

Management of hair loss after severe acute respiratory syndrome coronavirus 2 infection: Insight into the pathophysiology with implication for better management | Children and COVID-19: State level Data Report | FDA Announces Tentative Advisory Committee Meeting Schedule Regarding COVID- 19 Vaccines | FDA Advisory Committee Recommends Emergency Use Authorization of Novavax COVID-19 Vaccine for People Aged 18 Years and Older | Moderna announces omicron-containing bivalent booster candidate MRNA-1273.214 demonstrates superior antibody response against Omicron

IDSA Guideline on the Treatment and Management of COVID-19 with Famotidine | Children and COVID-19: State level Data Report | Duration of viable virus shedding in SARS-CoV-2 omicron variant infection | The association between pre-exposure to glucocorticoids and other immunosuppressant drugs with severe COVID-19 outcomes | Generalizable Long COVID Subtypes: Findings from the NIH N3C and RECOVER Programs | Rehabilitation Interventions for Post-Acute COVID-19 Syndrome: A Systematic | Tixagevimab/Cilgavimab for Prevention of COVID-19 during the Omicron Surge: Retrospective Analysis of National VA Electronic Data

Croup Associated With SARS-CoV-2: Pediatric Laryngotracheitis During the Omicron Surge | Rhinovirus as the main co-circulating virus during the COVID-19 pandemic in children | Children and COVID-19: State-Level Data Report | Infectious viral shedding of SARS-CoV-2 Delta following vaccination: a longitudinal cohort study | Pfizer-BioNTech COVID-19 Vaccine Demonstrates Strong Immune Response, High Efficacy and Favorable Safety in Children 6 Months to Under 5 Years of Age Following Third Dose | Protection of mRNA vaccines against hospitalized COVID-19 in adults over the first year following authorization in the United States

Gastrointestinal symptoms and fecal shedding of SARS-CoV-2 RNA suggest prolonged gastrointestinal infection | The Importance of Understanding the Stages of COVID-19 in Treatment and Trials | Supratherapeutic tacrolimus concentrations with Nirmatrelvir/ritonavir in solid organ transplant recipients requiring hospitalization: A case series using rifampin for | Inflammasome activation in infected macrophages drives COVID-19 pathology | Post-acute COVID-19 is characterized by gut viral antigen persistence in inflammatory bowel diseases | Limited cross-variant immunity from SARS-CoV-2 Omicron without vaccination

Effect of Early Treatment with Ivermectin among Patients with Covid-19 | Procalcitonin Is Not a Reliable Biomarker of Bacterial Coinfection in People With Coronavirus Disease 2019 Undergoing Microbiological Investigation at the Time of Hospital Admission | Children and COVID-19: State Date Report | Evaluation of mRNA-1273 Covid-19 Vaccine in Children 6 to 11 Years of Age | FDA Limits Use of Janssen COVID-19 Vaccine to Certain Individuals | Recall of B cell memory depends on relative locations of prime and boost immunization | Tixagevimab/Cilgavimab for Treatment of Hospitalised COVID-19 Patients: A Randomised, Double-Blind, Phase 3 Trial

FDA Updates on Paxlovid for Health Care Providers | SARS-CoV-2 Omicron Variant is as Deadly as Previous Waves After Adjusting for Vaccinations, Demographics, and Comorbidities | Comparative effectiveness over time of the mRNA-1273 (Moderna) vaccine and the BNT162b2 (Pfizer-BioNTech) vaccine